PubMed Health⌕ Search

Biomedical subjects

K Sampi

Publications and source records attributed to K Sampi.

At least 91 records · Page 5Linked to original sources
PubMed1983

Induction of differentiation of human acute non-lymphocytic leukemia cells in primary culture by inducers of differentiation of human myeloid leukemia cell line HL-60.

Leukemia cells from patients with acute non-lymphocytic leukemia were treated with various inducers of differentiation of the human promyelocytic leukemia cell line HL-60. All cells in 14 specimens tested underwent morphological, functional and histochemical changes after treatment with some inducers of differentiation of HL-60 cells, but the most effective inducer varied for different specimens. These results suggest that treatment with some inducers should be effective for inducing most acute myeloid leukemia cells to differentiate into morphologically and functionally mature granulocytes and macrophages.

Adult↗
PubMed1983

[Cyclophosphamide, adriamycin, vincristine, bleomycin and prednisolone (CHOP-Bleo) combination chemotherapy for advanced non-Hodgkin's lymphoma].

Nineteen patients with advanced non-Hodgkin's lymphoma (NHL) (stages III and IV) receiving no prior chemotherapy were treated with a combination of cyclophosphamide, adriamycin, vincristine, bleomycin and prednisolone (CHOP-Bleo) at Saitama Cancer Center between January 1977 and February 1979. The overall complete response rate was 11 of 19 or 50%, with 8 of 13 or 62% of patients with diffuse mixed and large cell type of NHL. The median survival for all patients was 41 months. The survival curve of complete responders became flat at 41 months and was well sustained with an actuarial survival of 72%. The survival of patients with stage III was significantly better than those with stage IV (p less than 0.05), while the survival of patients with Waldeyer's ring primary was not significantly superior to patients with nodal primary. A major complication during CHOP-Bleo regimen was myelosuppression, and peripheral neuropathy and reversible interstitial pneumonitis (2 cases) were also observed.

Adolescent↗
PubMed1983

[Phase II study of Vindesine in patients with hematological malignancy].

At Saitama Cancer Center a Phase II study of Vindesine was carried out in 18 patients with hematological malignancy being refractory to standard chemotherapies. Vindesine (VDS) was given weekly at a dose of 3 mg/m2 as single-agent chemotherapy. One cytoreduction effect (CE) in 5 patients with acute lympho blastic leukemia, two CEs in 2 patients with acute non-lymphocytic leukemia, one PR and one CE in 4 patients with CML/BC, three PRs in 3 patients with diffuse non-Hodgkin's lymphoma (NHL) of large cell type, one CR in 2 patients with lymphoblastic lymphoma and one PR in 2 patients with Burkitt's lymphoma were obtained. VDS was discontinued in two patients because of neurologic toxicities such as incontinence of urine, abdominal distension, and severe constipation.

Adult↗
PubMed1983

[Phase II study of a new anthraquinone antineoplastic agent, mitoxantrone, in hematological malignancies].

At Saitama Cancer Center a phase II study of mitoxantrone was carried out in 18 patients with hematological malignancy. Mitoxantrone was given at either doses of 3, 5, or 6 mg/m2 daily X 5 in 8 patients with acute leukemia, while 10 patients with NHL were given intravenously at a dose of 10, 12, or 14 mg/m2 every 3 to 4 weeks. Although remission was not obtained in patients with acute leukemia, severe hypoplastic marrow was induced in 3 patients. Of 10 patients with NHL, one achieved CR, and 4 had a PR which lasted 31 weeks, 27 weeks, 19 weeks, 12 weeks +, and 9 weeks+. These patients had previous exposure to anthracyclines. Gastrointestinal toxicity and alopecia were less frequently seen and less severe with mitoxantrone.

Adolescent↗
PubMed1983

[Prediction of resistance to remission induction in acute leukemia in adult].

Twenty-two patients with adult acute non-lymphocytic leukemia treated with intensive combination chemotherapy between November 1975 and April 1982 were retrospectively analyzed to see if we could find useful clinical parameters which could predict those patients who, after failing their initial treatment cycle, would respond to subsequent cycles of the same regimen. Three groups of patients were identified. Eight patients achieved complete remission with one cycle of chemotherapy; seven patients achieved complete remission with a second cycle of the same regimen and seven patients did not respond. Marrow studies performed approximately 3 weeks following the first cycle of therapy were analyzed. Patients who subsequently responded to the regimen differed from non-responders in the residual blasts percentage in the marrow obtained 20-24 days after the initiation of the first cycle. Patients who responded to a second cycle had 11-36% blasts (mean 24%), while non-responders had 35-96% blasts (mean 66%) (p less than 0.01). No patients with more than 40% blasts in their bone marrow achieved complete remission. We concluded that patients with more than 40% blasts in their bone marrow 20-24 days after the initiation of the first cycle of the chemotherapy regimens used should receive an alternate regimen for a second cycle of induction therapy.

Aclarubicin↗
PubMed1983

[Aclacinomycin A and behenoyl ara-C combination chemotherapy for untreated acute non-lymphocytic leukemia].

Sixteen patients with previously untreated acute nonlymphocytic leukemia were treated with a combination of aclacinomycin A (ACM-A) and behenoyl ara-C (BH-AC) at Saitama Cancer Center between April 1980 and February 1983. The complete remission was obtained in 10 of 16 patients (62.5%) (M1, 0/1 M2, 8/8, M3, 0/2, M4, 2/5). A combination of daunorubicin (DNR) and cytosine arabinoside (ARA-C) was crossed over to 5 patients who failed to respond to primary treatment of a combined ACM-A and BH-AC. All of these attained the complete remission. The cumulative dose of over 600 mg/m2 of ACM-A has been given to 7 patients as maintenance treatment. The maximum cumulative dose was 2000 mg/m2. The median survival time for all patients was 12 months, and the median survival with complete remission has not been reached; however, it is estimated to be greater than 24 months. ACM-A seemed to induce long-term maintenance when it was used as maintenance treatment. The results have demonstrated that a combination of ACM-A and BH-AC shows equivalent activity with that of a combined DNR and ARA-C in terms of remission induction and remission maintenance.

Aclarubicin↗
PubMed1983

[Combination therapy of vinca alkaloids and nicardipine in non-Hodgkin's lymphoma with resistant to various antineoplastic agents].

Three patients with non-Hodgkin's lymphoma who relapsed and were considered to be resistant to standard chemotherapeutic agents including vinca alkaloids were treated with a vinca alkaloid combined with calcium antagonist, nicardipine. All three patients showed some response to this treatment. Two of them were reentered into partial response at a dose of 1.0 mg of vincristine weekly and 40 mg of nicardipine, p.o., tid. From this result, it was suggested that the resistance to vinca alkaloids could be overcome and the cytotoxic effect of vinca alkaloids could be enhanced by nicardipine. The plasma concentration of nicardipine was variable in each patient and lower than initially expected. Overcome of drug resistance and enhancement of chemotherapeutic effect by nicardipine should be tried in the treatment of refractory non-Hodgkin's lymphoma.

Aged↗
PubMed1983

[Sulbenicillin and amikacin for febrile patients with cancer--with special reference to granulocytopenia].

Between March 1978 and March 1983 ninety-four episodes of fever in 56 mainly granulocytopenic patients with cancer were treated empirically with a combination of sulbenicillin (5.0 g, every 6 hours) and amikacin (200 mg, every 6 hours) in Saitama Cancer Center. Profound granulocytopenia at the beginning of treatment (less than 100/mm3 of granulocytes) was present in 66% of the patients. Oral absorbable or nonabsorbable antibiotics were used in 59 febrile episodes. WBC transfusion was not given. The response rate for all documented infections was 75%, including 10 of 13 (77%) of bacteremias. The majority of infections with identified organisms were caused by aerobic gram-negative bacilli: the major gram-negative pathogens being Ps. aeruginosa (11 cases), Klebsiella spp. (7 cases), E. coli (7 cases) and Enterobacter spp. (7 cases). The response rate of gram-negative bacilliary infections was 74%. Pneumonia responded less satisfactorily than all other types of infection with the response rate of 20%. The response rate of 69% for profound persistent granulocytopenia (less than 100/mm3 of granulocytes without a rise during therapy) is higher than that of any other reports. The most common adverse effect was hepatotoxicity (19%), whereas oliguria or anuria occurred in two patients, by which they eventually expired.

Adolescent↗
PubMed1982

A suprasellar embryonal carcinoma producing alpha-fetoprotein and human chorionic gonadotropin; treated with combined chemotherapy followed by radiotherapy.

A case of primary suprasellar embryonal carcinoma that produced alpha-fetoprotein and human chorionic gonadotropin in a 12-year-old girl is reported. Partial removal of the tumor and cis-platinum-based combined chemotherapy followed by local radiotherapy resulted in a definite regression of the tumor and improvement from clinical signs and symptoms. After these treatments, the concentrations of alpha-fetoprotein and human chorionic gonadotropin in both serum and cerebrospinal fluid decreased to undetectable levels. Serum basic fetoprotein, another tumor marker, can be a tool for evaluating the clinical course following postoperative chemotherapy.

Bleomycin↗
PubMed1982

An analysis of chromosome findings in non-Hodgkin's lymphomas.

Banding studies were done on tissues from tumors excised from 22 Japanese patients with non-Hodgkin's lymphomas. All tumors were found to be associated with aneuploidy. The chromosome abnormalities were diverse, with each chromosome type being involved in these abnormalities. Terminal deletions, derivative chromosomes as a result of unbalanced or nonreciprocal translocations, and markers of totally or partially unknown origin accounted for the majority of the structural abnormalities. Balanced reciprocal translocations were seen only occasionally. The 14q+, 6q-, partial trisomy of 1q, 11q+, 18q+, and 19q+ abnormalities were seen in more than two patients. The incidence of a missing sex chromosome was significantly higher than that of autosomes, but no particular other karyotypic abnormality seemed to be associated with the event. All six patients whose chromosomes could be totally characterized were in complete remission. Patients with one or more markers of unknown either totally or partially origin, had a median survival of only 8 months (p less than 0.01). Five of the former six patients showed a nodular histology. Fifteen of the latter 16 patients had a diffuse histology, with 13 of the 15 having diffuse histiocytic lymphoma. The median survival of 9.5 months for the 14 with only abnormal metaphases in the lymphatic tissues (AA-group) was shorter than the 26+ months for the seven patients with both normal and abnormal metaphases (AN-group). Thus certain aspects of chromosomal changes appear to correlate with histology and/or prognosis in non-Hodgkin's lymphomas.

Adolescent↗
PubMed1982

Burkitt's lymphoma with 2/8 translocation: a case report with special reference to the clinical features.

A case of Japanese Burkitt's lymphoma (BL) with a t(2; 8) (p11; q24), a variant translocation in BL, is reported. The patient was a 45-year-old woman in whom a subcutaneous right axillary tumor first occurred. Remission was not achieved despite extensive chemotherapy. Of the four nonendemic BL, two endemic BL, and one nonendemic Burkitt-type acute lymphocytic leukemia (ALL-L3) cases with a t(2; 8) reported so far, including the present case, four (two nonendemic and two endemic) were positive for Epstein-Barr virus-determined nuclear antigen (EBNA) and two revealed extremely high antibody titers against Epstein-Barr virus (EBV), the remaining one not having been tested for EBV. Thus, a possible close relationship between the t(2; 8) and EBV infection has to be considered. The t(2; 8) in nonendemic BL seems to occur more often in adults than in children.

Antigens, Viral↗
PubMed1982

[High dose methotrexate with leucovorin rescue in the treatment of malignant lymphoma].

Nineteen patients with malignant lymphomas were treated with 52 courses of high dose methotrexate with leucovorin rescue (HDMTX-LCV): 17 non-Hodgkin's lymphoma (11 nodal primary, and 6 Waldeyer's ring), 1 Hodgkin's disease, and 1 Burkitt's lymphoma; 10 No prior chemotherapy, 9 prior chemotherapy; Median age 50 years (18-67); Sex M 13:F 6. MTX was given according to Frei III et al's regimen(1975). In brief, alkalinization of the urine was achieved by administration of NaHCO3 both by oral and by intravenous route. Hydration with at least 3 liters of fluid per day was maintained throughout each course. MTX was administered as a six-hour infusion at an initial dose of 0.5-1.0 g/m2 with gradual escalation to 3-5 g/m2. Thirty minutes before the infusion of MTX, 1.4 mg/m2 of vincristine (VCR) (maximum dose 2 mg) was given intravenously in each course. MTX levels were not monitored. The overall response rate was 63% with 7 partial responses and 5 complete responses. Five of 10 previously untreated patients and 7 of 9 patients with prior chemotherapy achieved an objective response. Our excellent result may be contributed in part by VCR. Although, in general, during this study HDMTX-LCV was well-tolerated, a 67 year-old male had severe and unpredictable toxicity which resulted in shock condition, leukopenia and thrombocytopenia. Accordingly, we feel that HDMTX-LCV is dangerous without monitoring plasma MTX level. In other side effects, peripheral neuropathy and constipation possibly due to VCR occurred especially in elderly patients.

Adolescent↗